Taxonomy

Exploring New Therapeutic Pathways for CMT1B: UPR Activation

Researchers at the Ospedale San Raffaele (OSR) Scientific Institute in

Read More

Advancing the Understanding of CMT2A and CMT2F: A Call to Beat CMT

The Charcot-Marie-Tooth Association (CMTA), through its Strategy To Accelerate Research

Read More

Let’s Beat CMT – 2024 CMT Awareness Month

#LetsBeatCMT is a social media initiative during CMT Awareness Month

Read More

CMTA-STAR Alliance Partner Actio Biosciences Receives FDA Orphan Drug Designation and Rare Pediatric Disease Designation for Their Treatment in Development for CMT2C

The Charcot-Marie-Tooth Association (CMTA) is pleased to share exciting news

Read More

CMTA Alliance Partner Applied Therapeutics Plans to Submit an NDA for CMT-SORD, a Potential First Approval for the Treatment of any type of CMT

The Charcot-Marie-Tooth Association (CMTA) is pleased to share exciting news

Read More

Gene Replacement Therapy in CMT4 Subtypes

The Charcot-Marie-Tooth Association (CMTA) has announced a $240K investment in

Read More

Nanoparticles for CMT1A, CMT1B, and CMTX1: A New Frontier in Gene Therapy

In a groundbreaking three-year joint project between the Charcot-Marie-Tooth Association

Read More

Repurposing Drugs for CMT1A: An Encouraging Approach

Charcot-Marie-Tooth disease type 1A (CMT1A) is the most common form

Read More

DNA-Based Therapeutics: A Promising Future for CMT2E Treatment

Researchers at the University of Miami, supported by the Charcot-Marie-Tooth

Read More

CMT-SORD: Share Your Story

CMT-SORD: What is Your Story? For many with CMT, the

Read More